

# Cardiology Update

Royal Brompton & Harefield   
NHS Foundation Trust

22  
LONDON

Event endorsed by



## The 6<sup>th</sup> Royal Brompton & Harefield Christmas Postgraduate Course

The Royal Society of Medicine,  
1 Wimpole St, Marylebone, London  
December 12<sup>th</sup>–13<sup>th</sup>, 2022

### Course Directors

Prof. Thomas F. Lüscher, FRCP, FESC  
Dr. Richard Grocott–Mason, FRCP  
Prof. Kim Fox, FRCP, FESC  
Prof. Bernard J. Gersh, FACC  
Dr. Peter Libby, FACC

### Scientific Coordination

Dr. Ruth Amstein, FESC



ZÜRICH  
HEART HOUSE  
LONDON  
HEART HOUSE



THE YEAR IN CARDIOLOGY REVIEW

## Dear Colleagues

It is a real pleasure to welcome you to the 6th Christmas Postgraduate Course of the Royal Brompton and Harefield NHS Foundation Trust & Imperial College, the Cardiology Update London.

Cardiology and cardiovascular medicine in general is a rapidly expanding field with impressive developments and innovations over the last years. For physicians, be it general practitioners, cardiologists or cardiac surgeons, it is therefore important to keep pace with a challenging environment. To that end, we have designed a postgraduate course, the Cardiology Update London, to summarize, at the end of the year, the most important new developments, innovations, but also failures that will all affect cardiovascular diagnosis and management in our everyday practice.

We have selected an international Faculty of high standing experts both from the Trust and worldwide, covering the broad spectrum of cardiovascular medicine from prevention to intervention, from valvular heart disease to heart failure, and from conservative management to intervention and surgical operations. Thus, the course will give an up-to-date overview about current diagnosis and management of the most important cardiovascular conditions during two days in London.

We are delighted to welcome you at the Royal Society of Medicine in central London to enjoy two days of interactive education for the benefit of your practice and your patients.

Yours sincerely,



**Prof. Thomas F. Lüscher**  
MD, FRPC, FESC



**Dr. Richard Grocott-Mason**  
MD, FRCP



**Prof. Kim Fox**  
MD, FRCP, FESC



**Dr. Ruth Amstein**  
FESC



**Prof. Bernard J. Gersh**  
FACC



**Dr. Peter Libby**  
FACC

12		13	
Monday, December 12 <sup>th</sup> (UK Time)		Tuesday, December 13 <sup>th</sup> (UK Time)	
08:30	<b>Welcome Address</b>  <b>Opening Lectures</b> <ul style="list-style-type: none"> <li>Frontiers in cardiovascular science</li> </ul>	08:30	SESSION 4 <b>Arrhythmias, Sudden Cardiac Death</b> <ul style="list-style-type: none"> <li>The ESC Guidelines on Ventricular Arrhythmias and SCD</li> <li>Myocardial fibrosis and SCD</li> <li>Long Covid, PODS</li> <li>Atrial fibrillation 2022</li> </ul>
09:45	COFFEE	10:30	COFFEE
10:15	SESSION 1 <b>Risk Factors and Prevention</b> <ul style="list-style-type: none"> <li>Dyslipidaemias</li> <li>Lipoprotein(a)</li> <li>Heart age</li> </ul>	11:00	SESSION 5 <b>Valve Disease</b> <ul style="list-style-type: none"> <li>Advanced imaging in aortic stenosis</li> <li>TAVI, the default option in AS?</li> <li>Mitral valve disease</li> <li>Tricuspid regurgitation</li> </ul>
12:30	<b>Satellite Symposium</b>	12:30	<b>Satellite Symposium</b>
13:15	LUNCH BREAK	13:15	LUNCH BREAK
14:00	SESSION 2 <b>Acute and Chronic Coronary Syndromes</b> <ul style="list-style-type: none"> <li>Diagnostic procedures and imaging</li> <li>What is predictive in CCS?</li> <li>Acute management of ACS</li> <li>Antithrombotic therapy</li> </ul>	14:00	<b>The Paul Hamilton Wood Lecture</b> The HF Saga (M. Packer)
		14:30	SESSION 6 <b>Heart Failure: Established and Novel Drugs/Advanced Stage</b> <ul style="list-style-type: none"> <li>Guideline-directed medical therapy</li> <li>New and emerging therapies</li> <li>Mechanical circulatory support for destination therapy</li> </ul>
16:15	COFFEE	15:45	COFFEE
16:45	<b>Satellite Symposium</b>		
17:15	SESSION 3 <b>The new ESC Guidelines</b> <ul style="list-style-type: none"> <li>Pulmonary Hypertension</li> <li>Cardiovascular Management of patients with non-cardiac surgery</li> <li>Cardio-Oncology</li> </ul>	16:00	SESSION 7 <b>Heart, Kidney and Amyloidosis</b> <ul style="list-style-type: none"> <li>Kidney protection by SGLT2 Inhibitors</li> <li>Clinical use of biomarkers in HF</li> <li>Transthyretin amyloidosis</li> </ul>
18:30	NETWORKING RECEPTION	17:15	ADJOURN

## Monday, December 12<sup>th</sup>, 2022 (UK time)

Venue: The Royal Society of Medicine

<b>08:30 – 09:00</b>		
<b>Welcome Address</b>		
08:30	Welcome by the ESC President-Elect: The future of Cardiology in Europe	Thomas F. Lüscher, London
<b>08:45 – 09:45</b>		
<b>Opening Lectures: Frontiers in Cardiovascular Science</b>		
Chair: Thomas F. Lüscher, London and Filippo Crea, Rome		
08:45	Opening Lecture 1: The vulnerable patient: Imaging residual inflammatory cardiovascular risk	Charalambos Antoniades, Oxford
09:15	Opening Lecture 2: Digital health in current clinical practice	Martin Cowie, London
<b>09:45 – 10:15</b>		
COFFEE BREAK		
<b>10:15 – 12:30</b>		
<b>Session 1: Risk Factors and Prevention</b>		
Chair: Mahmoud Barbir, Harefield and Ulf Landmesser, Berlin		
10:15	Mischief in the marrow: A root of cardiovascular diseases	Peter Libby, Boston
10:35	RNA interference to treat hyperlipidaemia	Ulf Landmesser, Berlin
10:55	Novel antilipidaemic drugs	François Mach, Geneva
11:15	Lipoprotein(a) – the Cinderella of lipid management (Apollo Trial)	Børge Nordestgaard, Copenhagen
11:35	Heart age: A new concept to implement prevention	John Deanfield, London
11:55	Panel Discussion	
<b>12:30 – 13:15</b>		
<b>Industry Sponsored Symposium</b>		
<b>13:15 – 14:00</b>		
LUNCH BUFFET		
<b>14:00 – 16:15</b>		
<b>Session 2: Acute and Chronic Coronary Syndromes</b>		
Chair: Richard Grocott-Mason, London and Peter Libby, Boston		
14:00	Which imaging modality to diagnose ischemia? (PACIFIC and DISCHARGE Trials)	Ibrahim Danad, Amsterdam
14:15	What is predictive in CCS: Ischemia or coronary anatomy?	Bernard J. Gersh, Rochester MN
14:30	Supported PCI in cardiogenic shock (interactive voting)	Majid Akhtar, London

14:45	Inflammation and ACS	Filippo Crea, Rome
15:00	Acute management of ACS: What we think we know and what we would like to know in the future	Adrian Banning, Oxford
15:15	Effects of PCSK9 inhibition on coronary atherosclerosis and AMI (PACMAN AMI Trial)	Lorenz Räber, Berne
15:30	Towards personal antithrombotic management in ACS	Thomas F. Lüscher, London
15:45	Panel discussion	

**16:15 – 16:45** COFFEE BREAK

**16:45 – 17:15** Industry Sponsored Symposium

**17:15 – 18:30** Session 3: The new ESC 2022 Guidelines

Chair: François Mach, Geneva and Bernard J. Gersh, Rochester MN

17:15	Pulmonary Hypertension	Stephan Rosenkranz, Cologne
17:30	Q & A	
17:40	Cardio-Oncology	Alexander Lyon, London
17:55	Q & A	
18:05	Cardiovascular management of patients with non-cardiac surgery	Julinda Mehilli, Landshut-Achdorf
18:20	Q & A	

**18:30** GET TOGETHER RECEPTION

## Tuesday, December 13<sup>th</sup>, 2022 (UK time)

**08:30 – 10:30** Session 4: Arrhythmias, Sudden Cardiac Death

Chair: A. John Camm, London and Vias Markides, London

08:30	2022 ESC Guidelines on Ventricular Arrhythmias and SCD	Jacob Tfelt-Hansen, Copenhagen
08:50	My patient with ventricular arrhythmias (interactive voting)	Shouvik Halder, London
09:10	Myocardial fibrosis and SCD	Sanjay Prasad, London

09:30	Long Covid, PODS and other conditions	Betty Raman, Oxford
09:50	Atrial fibrillation 2022	Gerhard Hindricks, Leipzig
10:10	Panel discussion	

**10:30 – 11:00** COFFEE BREAK

**11:00 – 12:30** **Session 5: Valve Disease**  
Chair: Miles Dalby, London and Volkmar Falk, Berlin

11:00	Advanced imaging in aortic stenosis	Jeroen J. Bax, Leiden
11:20	TAVI, the default option in aortic stenosis?	Stephan Windecker, Berne
11:40	Mitral valve disease: Knife or clip?	Francesco Maisano, Milano
12:00	Tricuspid regurgitation, a new therapeutic target	Georg Nickenig, Bonn
12:20	Panel discussion	

**12:30 – 13:15** **Industry Sponsored Symposium**

**13:15 – 14:00** LUNCH BUFFET

**14:00 – 14:30** **The Paul Hamilton Wood Lecture**  
Chairs: Bernard J. Gersh, Rochester MN and Thomas F. Lüscher, London

	The Heart Failure Saga	Milton Packer, Dallas
--	------------------------	-----------------------

**14:30 – 15:45** **Session 6: Heart Failure: Established and Novel Drugs/Advanced Stage**  
Chair: Paul Kalra, Portsmouth and Giuseppe Rosano, London

14:30	Guideline-directed medical therapy in HFrEF	Theresa McDonagh, London
14:50	New and emerging therapies in HF: Cyclic GMP activation and beyond	Piotr Ponikowski, Wroclaw
15:10	Mechanical circulatory support for destination therapy	Volkmar Falk, Berlin
15:30	Panel discussion	

**15:45 – 16:00** COFFEE BREAK

<b>16:00 – 17:15</b>	<b>Session 7: Heart, Kidney and Amyloidosis</b> Chair: Bernard J. Gersh, Rochester and Antonis Pantazis, London	
16:00	Kidney protection by SGLT2 inhibitors	Christoph Wanner, Würzburg
16:20	Clinical use of biomarkers in HF	Alan Maisel, San Diego
16:40	Transthyretin amyloidosis: Diagnosis and outcome	Martha Grogan, Rochester MN
17:00	Panel discussion	
<b>17:15</b>	<b>WRAP-UP AND ADJOURN</b> Thomas F. Lüscher, London	

## Satellite Symposia

### Monday, December 12<sup>th</sup>, 2022

<b>12:30 – 13:15</b>	<b>Industry Sponsored Symposium: Cardio-renal disease</b> This is a promotional symposium sponsored and organised by AstraZeneca	
12:30 – 13:15	Improving outcomes for your patients with cardio-renal disease	TBC
<b>16:45 – 17:15</b>	<b>Industry Sponsored Symposium: Hereditary Transthyretin-Mediated Amyloidosis: New horizons with RNAi therapeutics</b> Sponsored by Alnylam Chair: Carol Whelan, London	
16:45	Efficacy of patisiran on cardiac structure and function in hATTR amyloidosis: The APOLLO-B Study	Martha Grogan, Rochester MN
17:00	Beneficial effect of Vutrisiran on cardiac parameters and optimised dosage schedule (HELIOS-A Study)	Carol Whelan, London

### Tuesday, December 13<sup>th</sup>, 2022

<b>12:30 – 13:15</b>	<b>Industry Sponsored Symposium: CRT</b> Sponsored by Abbott	
12:30 – 13:15	CRT results are great – but could they be better?	Niraj Varma, London

Mohammed Majid Akhtar  
London, UK

Charalambos Antoniades  
Oxford, UK

Adrian Banning  
Oxford, UK

Mahmoud Barbir  
London, UK

Jeroen J. Bax  
Leiden, NL

A. John Camm  
London, UK

Martin Cowie  
London, UK

Filippo Crea  
Rome, IT

Miles Dalby  
London, UK

Ibrahim Danad  
Amsterdam, NL

John E. Deanfield  
London, UK

Volkmar Falk  
Berlin, DE

Kim Fox  
London, UK

Bernard J. Gersh  
Rochester MN, USA

Richard Grocott-Mason  
London, UK

Martha Grogan  
Rochester MN, USA

Shouvik Haldar  
London, UK

Gerhard Hindricks  
Leipzig, DE

Paul Kalra  
Portsmouth, UK

Ulf Landmesser  
Berlin, DE

Peter Libby  
Boston, USA

Thomas F. Lüscher  
London, UK

Alexander Lyon  
London, UK

François Mach  
Geneva, CH

Francesco Maisano  
Milan, IT

Alan S. Maisel  
San Diego, USA

Vias Markides  
London, UK

Theresa A. McDonagh  
London, UK

Julinda Mehilli  
Landshut, DE

Georg Nickenig  
Bonn, DE

Børge Nordestgaard  
Herlev, NL

Milton Packer  
Dallas, USA

Antonis Pantazis  
London, UK

Piotr Ponikowski  
Wroclaw, PL

Sanjay Prasad  
London, UK

Lorenz Räber  
Berne, CH

Betty Raman  
Oxford, UK

Giuseppe Rosano  
London, UK

Stephan Rosenkranz  
Cologne, DE

Jacob Tfelt-Hansen  
Copenhagen, DK

Niraj Varma  
London, UK

Christoph Wanner  
Würzburg, DE

Carol Whelan  
London, UK

Stephan Windecker  
Berne, CH



### Registration

Registrations can be made exclusively online on our website: [www.cardiologyupdate.uk](http://www.cardiologyupdate.uk)

Early registration fee (until November 11, 2022)	GBP 250
Regular registration fee	GBP 300
Residents, students (age < 35) early fee*	GBP 100
Residents, students (age < 35) regular fee*	GBP 150
Day ticket	GBP 150

\* ID proof required

Registration will be confirmed upon receipt of payment.

### ESC / Association Members

Early fee ESC / Association Members (until November 11, 2022)	GBP 200
Regular fee ESC / Association Members	GBP 250

### Group Registration

For group registrations a minimum of 10 participants is required.

Regular registration fee	GBP 260
Early registration fee (until November 11, 2022)	GBP 210

Please contact Mrs. Nadine-Estelle Abea ([nadine-estelle.abea@zhz.ch](mailto:nadine-estelle.abea@zhz.ch)) at the Zurich Heart House to obtain further information.



### Modification & Cancellation

All modifications or cancellations must be notified in writing (by mail, fax or e-mail) to the Zurich Heart House. For each modification requested by the participant, GBP 50 will be charged for administrative costs. In case of cancellation up to **1<sup>th</sup> of November 2022**, deposits will be refunded less 35% for administrative costs. After this date, no refund will be possible.

**Accreditation**

The Cardiology Update London is recognised by the following institutions as accredited continuing education:

- Federation of the Royal Colleges of Physicians of the United Kingdom for CPD credits  
**13 category 1 (external) CPD credits**
- EACCME-UEMS  
European Accreditation Council for Continuing Medical Education (EACCME®)  
**13 European CME credits (ECMEC®s)**



Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

- British Cardiovascular Society



In collaboration with



Event endorsed by

Under the Auspices of



### Venue

The Royal Society of Medicine,  
1 Wimpole St, Marylebone, London W1G 0AE, United Kingdom

### Organisation

#### Zurich Heart House, Foundation for Cardiovascular Research

Dr. Ruth Amstein (ruth.amstein@zhh.ch)

Nadine-Estelle Abea (nadine-estelle.abea@zhh.ch)

Hottingerstrasse 14, CH-8032 Zurich, Switzerland

Phone +41 (0) 44 250 40 95, Fax +41 (0) 44 250 40 90

[www.cardiologyupdate.uk](http://www.cardiologyupdate.uk)

### Acknowledgement

Supported by an Educational Grant of H. H. Sheikh Khalifa  
Bin Hamad Al-Thani.

---

### Platinum Sponsors



---

### Gold Sponsor



The sponsoring grants are used exclusively for the organisation of the scientific programme.

\*AstraZeneca has provided a sponsorship grant towards this independent Programme.

AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations.

